FibroBiologics, Inc. — financial figures as filed
CIK 1958777 · 5 fiscal years on record
Aggregates
computed from the figures belowExplainable annual analytics
latest annual period where both published inputs exist| Metric | Value | Fiscal year | Inputs | Source tags |
|---|---|---|---|---|
| Return on assets | -193.8% | FY2025 | Net income: -$18.6MTotal assets: $9.6M | NetIncomeLoss / Assets |
| Return on equity | -302.9% | FY2025 | Net income: -$18.6MShareholders equity: $6.2M | NetIncomeLoss / StockholdersEquity |
| Liabilities / assets | 36.0% | FY2025 | Total liabilities: $3.5MTotal assets: $9.6M | Liabilities / Assets |
| Cash / assets | 50.9% | FY2025 | Cash and equivalents: $4.9MTotal assets: $9.6M | CashAndCashEquivalentsAtCarryingValue / Assets |
Not computed: Gross margin — both metrics are not available for a common annual period; Operating margin — both metrics are not available for a common annual period; Net margin — both metrics are not available for a common annual period; Operating cash-flow margin — both metrics are not available for a common annual period.
Mapping completeness
9 of 129 of 12 canonical metrics were filled from this company's filings through the explicit tag map. Tags outside that map are recorded and counted, and are never used as a value.
Not on record for this company: Revenue, Gross profit, Shares outstanding. This means the figure was not disclosed in a form we accept, not that it is zero.
Annual figures
5 fiscal years shown| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M | — |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M | — |
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M | -$4.1M | — |
| Total assets | $9.6M | $16.4M | $11.8M | $4.8M | — |
| Total liabilities | $3.5M | $13.7M | $10.6M | $8.8M | — |
| Shareholders equity | $6.2M | $2.7M | $1.3M | -$4M | -$1.3M |
| Cash and equivalents | $4.9M | $14M | $9.2M | $2.3M | — |
| EPS, basic | -$0.42 | -$0.34 | -$0.68 | -$0.18 | — |
| EPS, diluted | -$0.42 | -$0.34 | -$0.68 | -$0.18 | — |
Quarterly figures
10 fiscal quarters shown| Metric | 2026 Q1 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$5.1M | -$5M | -$4.5M | -$4.5M | -$3.4M | -$3.2M | -$3.5M | -$2.1M | -$2.1M | -$2.3M |
| Net income | -$5M | -$5.8M | -$4.7M | -$5M | -$500K | $898K | -$8.5M | -$2.2M | -$2.2M | -$2.4M |
| Operating cash flow | -$4.4M | — | — | -$5.3M | — | — | -$4.3M | — | — | -$2M |
| Total assets | $5.9M | $8.7M | $13.9M | $11.4M | $10.5M | $8.9M | $11.4M | — | — | — |
| Total liabilities | $3.3M | $8.6M | $13M | $9.1M | $7.7M | $11.3M | $15.3M | — | — | — |
| Shareholders equity | $2.6M | $125K | $860K | $2.4M | $2.7M | -$2.4M | -$3.9M | $10.5M | $11.4M | $639K |
| Cash and equivalents | $1.5M | $4.9M | $8.8M | $8.7M | $7.8M | $6M | $8.2M | — | — | — |
| EPS, basic | -$1.33 | -$0.13 | -$0.12 | -$0.14 | -$0.01 | $0.03 | -$0.27 | -$0.08 | -$0.08 | -$0.18 |
| EPS, diluted | -$1.33 | -$0.13 | -$0.12 | -$0.14 | -$0.01 | $0.03 | -$0.27 | -$0.08 | -$0.08 | -$0.18 |
Latest figure against the peer median
all 722 companies with figures on record| Metric | Latest annual figure | Peer median | Difference | Companies in group | Source tag |
|---|---|---|---|---|---|
| Operating income · FY2025 | -$16.6M | -$3.8M | −338.7% | 591 | OperatingIncomeLoss |
| Net income · FY2025 | -$18.6M | $2.4M | −862.0% | 716 | NetIncomeLoss |
| Operating cash flow · FY2025 | -$16.4M | $20.1M | −181.5% | 715 | NetCashProvidedByUsedInOperatingActivities |
| Total assets · FY2025 | $9.6M | $1.1B | −99.1% | 720 | Assets |
| Total liabilities · FY2025 | $3.5M | $458.2M | −99.2% | 664 | Liabilities |
| Shareholders equity · FY2025 | $6.2M | $301M | −98.0% | 716 | StockholdersEquity |
| Cash and equivalents · FY2025 | $4.9M | $82.6M | −94.1% | 688 | CashAndCashEquivalentsAtCarryingValue |
| EPS, basic · FY2025 | -$0.42 | $0.05 | −940.0% | 678 | EarningsPerShareBasic |
| EPS, diluted · FY2025 | -$0.42 | $0.03 | −1,780.0% | 678 | EarningsPerShareDiluted |
Where the numbers come from
every figure traces to a filing| Metric | Fiscal period | Period end | Filed | Form | Accession | XBRL tag |
|---|---|---|---|---|---|---|
| Operating income | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | OperatingIncomeLoss |
| Net income | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | NetIncomeLoss |
| Operating cash flow | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | NetCashProvidedByUsedInOperatingActivities |
| Total assets | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | Assets |
| Total liabilities | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | Liabilities |
| Shareholders equity | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | StockholdersEquity |
| Cash and equivalents | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | CashAndCashEquivalentsAtCarryingValue |
| EPS, basic | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | EarningsPerShareBasic |
| EPS, diluted | FY2025 | 2025-12-31 | 2026-02-24 | 10-K | 0001193125-26-066965 | EarningsPerShareDiluted |
Source: U.S. Securities and Exchange Commission, EDGAR company facts · as of 2026-02-24